The minimum percent of the amount of fat aspirated of body weight during the procedure was 7% and the maximum was 22%. Incidence of anemia was 8% of cases. The Results were evaluated by patient's satisfaction score (from 0 to 30). 41 patients reported a score of (25-30), 5 reported (20-25), 2 reported (15-20) and 2 reported (10-15). The latter 4 patients had minor complications like Seroma and excessive fatigue and tiredness.
Pharmacologic treatments aimed at mitigating radiationinduced injury have the potential to improve outcomes among these patients. Specifically, recent studies in our laboratory suggest deferoxamine (DFO) is capable of reducing skin ulceration and collagen fibril disorganization following radiation. What remains unclear, however, is whether breast cancer cells are concomitantly protected, a factor that would worsen cancer-specific outcomes among patients undergoing reconstruction. The purpose of this study is to determine the impact of DFO delivered in combination with XRT on breast cancer cell proliferation to ensure that tumor growth will not be concomitantly enhanced given the obvious improvements in skin viability resulting from DFO treatment.
METHODS:
Two triple-negative breast cancer cell lines, MDA-MB-231 and MDA-MB-468, were obtained from the University of Michigan Comprehensive Cancer Center and grown in culture. The dose-dependent effect of XRT (0, 5, and 10Gy) and DFO (0, 25, 50, 75 , and 100µM) on proliferation of each cell line was determined via hemocytometer. Then, the radiosensitivity of these cell lines was determined at 10Gy of XRT and increasing doses of DFO.
All three experiments were replicated via an MTS assay, a colorimetric assay for assessing cell metabolic activity, to fortify the results. All experiments were performed in triplicate. Statistical analysis was performed at p<0.05 significance using SPSS. , p=0.04). The sensitivity of both triplenegative breast cancer cell lines to 10Gy of XRT increased with the delivery of DFO, as evidenced by the significant decrease in cell number at 100µM DFO compared to 0µM DFO (p=0.00, p=0.00). Percent viability, which was quantitatively determined utilizing an MTS assay, significantly decreased in both cell lines in response to 10Gy XRT (MDA-MB-231: 100% to 77%, p=0.00; MDA-MB-468: 100% to 76%, p=0.04) and 25µM DFO (MDA-MB-231: 100% to 84%, p=0.00; MDA-MB-468: 100% to 56%, p=0.00) administered independently. Finally, 100µM DFO increased the sensitivity of MDA-MB-231 (100% to 90%, p=0.01) and MDA-MB-468 (100% to 71%, p=0.04) cells to 10Gy XRT.
RESULTS:

CONCLUSION:
XRT and DFO significantly decreased breast cancer cell proliferation when delivered independently and in combination. In a complementary fashion to previously published studies on iron chelation and cancer proliferation, 2 this study provides evidence that DFO may be safely utilized to facilitate improved surgical, aesthetic, and quality of life outcomes without increasing tumorigenesis among patients with triple-negative breast cancer.
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PURPOSE:
Eliminating healthcare disparities is a major priority as the United States population diversifies. Literature focusing on identifying disparities in postmastectomy breast reconstruction continues to expand. However, no study has assessed whether this research is progressing appropriately to promote tangible intervention in reducing disparities. The purpose of this study is to utilize a previously established public health framework for advancing health disparities research to evaluate the current state of breast reconstruction disparities research and provide literature-based recommendations for interventions.
METHODS:
A systematic literature review was performed in accordance with the preferred reporting items for systematic reviews and meta-analysis (PRISMA) to identify studies evaluating disparities in postmastectomy breast reconstruction. Results were analyzed according to the Kilbourne model, which categorizes disparities research into one of three phases: detecting (identifies and measures disparities in vulnerable populations), understanding (establishes determinants of disparities at the individual/systemic level) and reducing (proposes and evaluates interventions for eliminating disparities). 
CONCLUSION:
Despite the expanding pool of research on postmastectomy breast reconstruction disparities, the majority of this research focuses on detecting disparities with inadequate progression to second (understanding) and third (reducing) phase studies. The PRS community should take increasing ownership of this issue and promote higher-phase disparities research, as over half of published research exists in non-PRS journals. Increasing research funding, availability of language-and culturally concordant educational materials, as well as advocacy and sociopolitical awareness within the plastic surgery community is
